SecBot SecBot

PPCB

Propanc Biopharma, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001517681 Biotech & Drug Discovery
—
Market cap
$2.8M
Nano cap
Short interest
71.2K
≈0.7% of shares · +145.4%
Days to cover
1.0
at average volume
Filing reports
6
analyzed by SecBot
SecBot read BEARISH 4 reports · 90 days
Balance 1 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 3/4
Strongest BEARISH Propanc Biopharma filed an S-1 registration statement for the resale of up to 6,500,000 shares of common…
All reports →

Price

Daily candles with volume.

Signal stack

Where each data set points today.

  • Short sellersBUILDING

    Short interest +145.4% to 71.2K shares. 1.0 days to cover, ≈0.7% of shares.

Who's buying

13F
Top holderSharesValue
JANE STREET GROUP, LLC25,550$38.3K
CITADEL ADVISORS LLC12,090$18.1K
HRT FINANCIAL LP10,242$15.0K

Quarterly 13F filings are due 45 days after each quarter ends.

Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 Trading halt
🔒 Fresh data, subscribers only
Oct 22, 2026 Press
Propanc Biopharma announced a 1-for-10 reverse stock split effective October 26, 2026, to regain compliance with…
Impact 4/10
Oct 5, 2026 SEC
Propanc Biopharma filed an S-1 registration statement for the resale of up to 6,500,000 shares of common stock by…
S-1 — Impact 6/10
Sep 29, 2026 SEC
Propanc Biopharma reported a year-end net loss of $18.86M for FY2026, improved from a $58.92M loss in FY2025, with…
PRESS-RELEASE — Impact 4/10
Aug 18, 2026 Press
Propanc Biopharma announced it is finalizing a clinical trial protocol and conducting a feasibility assessment for a…
Impact 4/10
Jul 14, 2026 SEC
Propanc Biopharma reported the retirement of independent director Annie Van Broekhoven and the appointment of Carlo…
8-K — Impact 3/10

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Sep 30, 2026
71,162
shares short
+145.4%
vs prior settlement
1.0
days to cover
≈0.7%
of shares outstanding
Trading halts
Oct 23, 2026Resumption ScheduledResumed
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 26, 2026
Trading halt
🔒 Fresh data, subscribers only
Oct 26, 2026
Press release
🔒 Fresh data, subscribers only
Oct 23, 2026
Trading halt
🔒 Fresh data, subscribers only
Oct 23, 2026
Trading halt
Trading Halt: PPCB — T1 (News Pending)
Propanc Biopharma CMN | Market: NASDAQ | Code: T1 — News Pending
Oct 22, 2026
Activist
CORRECTION -- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans

SecBot reports

6 filings · 7 press releases · 0 bullish · 1 bearish · 5 neutral
All PPCB filing & press-release reports (13)